Brief: Genocea Presents Preclinical Research That Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses
05/11/2019 13:22
Nov 5 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA PRESENTS PRECLINICAL RESEARCH THAT SHOWS
INHIBITORY
NEOANTIGENS STIFLE PROTECTIVE ANTI-TUMOR IMMUNE RESPONSES AT
SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)
Source text for Eikon: ID:nGNXQpK2D
Further company coverage: GNCA.O
((Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc